Calzone; Frank J
Patent Applications and Registrations
Patent applications and USPTO patent grants for Calzone; Frank J.The latest application filed is for "treatment of autoimmune and inflammatory disorders using antibodies that bind interleukin-17a (il-17a)".
Company Profile
7.22.21
- Calzone; Frank J - Westlake Village CA
- Calzone; Frank J. - Westlake Village CA
- CALZONE, FRANK J. - WEST LAKE VILLAGE CA
- Calzone; Frank J. - Pine Crest Circle CA
- Calzone, Frank J. - Westlake CA
Patent Activity
| Patent | Date |
|---|---|
| Immunotherapy using antibodies that bind programmed death ligand-1 (PD-L1) Grant 11,332,531 - Calzone , et al. May 17, 2 | 2022-05-17 |
| Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4) Grant 11,319,372 - Calzone , et al. May 3, 2 | 2022-05-03 |
| Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer Grant 11,319,376 - Calzone May 3, 2 | 2022-05-03 |
| Immunotherapy using antibodies that bind Programmed Death 1 (PD-1) Grant 11,248,049 - Calzone , et al. February 15, 2 | 2022-02-15 |
| Anti-OX40 antibodies and methods of activating OX40 Grant 11,242,398 - Calzone , et al. February 8, 2 | 2022-02-08 |
| Methods and compositions for treating tumor diseases Grant 11,078,288 - Beltran , et al. August 3, 2 | 2021-08-03 |
| Treatment Of Autoimmune And Inflammatory Disorders Using Antibodies That Bind Interleukin-17a (il-17a) App 20210079087 - Calzone; Frank J ; et al. | 2021-03-18 |
| Cancer Treatment Using Antibodies That Bind Human Cd134 (ox40) Receptor App 20210024640 - Calzone; Frank J ; et al. | 2021-01-28 |
| Calcitonin Gene-related Peptide (cgrp) Antagonist Antibodies App 20200407433 - Calzone; Frank J ; et al. | 2020-12-31 |
| Immunotherapy Using Antibodies That Bind Programmed Death Ligand-1 (pd-l1) App 20200190197 - Calzone; Frank J. ; et al. | 2020-06-18 |
| Cancer Treatment Using Antibodies That Bind Cytotoxic T-lymphocyte Antigen-4 (ctla-4) App 20200055937 - Calzone; Frank J ; et al. | 2020-02-20 |
| Immunotherapy Using Antibodies That Bind Programmed Death 1 (pd-1) App 20190330346 - Calzone; Frank J ; et al. | 2019-10-31 |
| Combination Of Glucagon Receptor Antagonists And Pi3k Pathway Inhibitors For The Treatment Of Cancer App 20190169300 - Calzone; Frank J | 2019-06-06 |
| Methods And Compositions For Treating Tumor Diseases App 20190040141 - BELTRAN; Pedro J. ; et al. | 2019-02-07 |
| Compositions and methods relating to anti-IGF-1 receptor antibodies Grant 10,035,861 - Calzone , et al. July 31, 2 | 2018-07-31 |
| Compositions and Methods Relating to Anti-IGF-1 Receptor Antibodies App 20150274829 - CALZONE; Frank J. ; et al. | 2015-10-01 |
| Compositions and methods relating to anti-IGF-1 receptor antibodies Grant 8,895,008 - Calzone , et al. November 25, 2 | 2014-11-25 |
| Compositions and Methods Relating to Anti-IGF-1 Receptor Antibodies App 20130236457 - CALZONE; Frank J. ; et al. | 2013-09-12 |
| Compositions and methods relating to anti-IGF-1 receptor antibodies Grant 8,460,662 - Calzone , et al. June 11, 2 | 2013-06-11 |
| Compositions And Methods Relating To Anti-igf-1 Receptor Antibodies App 20120237516 - Calzone; Frank J. ; et al. | 2012-09-20 |
| Compositions and methods relating to anti-IGF-1 receptor antibodies Grant 8,168,409 - Calzone , et al. May 1, 2 | 2012-05-01 |
| Compositions and Methods Relating to Anti-IGF-1 Receptor Antibodies App 20110070615 - Calzone; Frank J. ; et al. | 2011-03-24 |
| Compositions and methods relating to anti IGF-1 receptor antibodies Grant 7,871,611 - Calzone , et al. January 18, 2 | 2011-01-18 |
| Osteoprotegerin App 20100298229 - BOYLE; William J. ; et al. | 2010-11-25 |
| Methods And Compositions For Treating Tumor Diseases App 20100166747 - Beltran; Pedro J. ; et al. | 2010-07-01 |
| Osteoprotegerin Grant 7,632,922 - Boyle , et al. December 15, 2 | 2009-12-15 |
| Compositions and methods relating to anti IGF-1 receptor antibodies App 20090285824 - Calzone; Frank J. ; et al. | 2009-11-19 |
| Combination therapy for conditions leading to bone loss Grant 7,005,413 - Boyle , et al. February 28, 2 | 2006-02-28 |
| Osteoprotegerin App 20050221331 - Boyle, William J. ; et al. | 2005-10-06 |
| Combination therapy for conditions leading to bone loss App 20050147611 - Boyle, William J. ; et al. | 2005-07-07 |
| Nucleic encoding interleukin-1 receptor antagonist-like proteins and uses thereof App 20050123512 - Calzone, Frank J. ; et al. | 2005-06-09 |
| HER-2/neu overexpression abrogates growth inhibitory pathways Grant 6,767,541 - Slamon , et al. July 27, 2 | 2004-07-27 |
| Osteoprotegerin App 20030207827 - BOYLE, WILLIAM J. ; et al. | 2003-11-06 |
| Osteoprotegerin Grant 6,613,544 - Boyle , et al. September 2, 2 | 2003-09-02 |
| CD20/IgE-receptor like molecules and uses thereof App 20020064823 - Welcher, Andrew A. ; et al. | 2002-05-30 |
| HER -2/neu overexpression abrogates growth inhibitory pathways App 20020051785 - Slamon, Dennis J. ; et al. | 2002-05-02 |
| Osteoprotegerin Grant 6,369,027 - Boyle , et al. April 9, 2 | 2002-04-09 |
| Osteoprotegerin Grant 6,288,032 - Boyle , et al. September 11, 2 | 2001-09-11 |
| Osteoprotegerin Grant 6,284,728 - Boyle , et al. September 4, 2 | 2001-09-04 |
| Osteoprotegerin Grant 6,284,740 - Boyle , et al. September 4, 2 | 2001-09-04 |
| Nucleic acids encoding osteoprotegerin Grant 6,284,485 - Boyle , et al. September 4, 2 | 2001-09-04 |
| Osteoprotegerin Grant 6,015,938 - Boyle , et al. January 18, 2 | 2000-01-18 |
Company Registrations
| NCAGE Code | 4YXS8 | CALZONE, FRANK J |
| CAGE Code | 4YXS8 | CALZONE, FRANK J |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 